Agendia develops and markets genomic diagnostic products for oncology, including the MammaPrint 70-gene risk-of-recurrence test and the BluePrint molecular subtyping test, both on microarray technology, plus a new MammaPrint BluePrint test on NGS. Led by CEO Mark R. Straley and based in Irvine, CA and Amsterdam, the company also has a pipeline of additional genomic products in development. Agendia collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostics. The company plans to use new financing to accelerate commercial expansion in the U.S. and international markets and to increase adoption of its sequencing-based MammaPrint BluePrint kit. It will invest in Big Data programs, including full-genome profiling trials FLEX (U.S.) and PRECiSE (Netherlands), and establish collaborative research programs with academic institutions to advance its precision oncology pipeline. Agendia develops and markets genomic-based cancer diagnostic products, principally the Symphony™ suite of breast cancer tests including MammaPrint and BluePrint. MammaPrint is FDA‑cleared and is described in the release as the company’s flagship, fastest‑growing, cost‑effective breast cancer recurrence assay; Symphony also includes TargetPrint and TheraPrint for molecular subtyping and therapy selection. The company was formed in 2003 as a spin‑out from the Netherlands Cancer Institute and is privately owned. In March 2014 Norgine Ventures led a €15 million debt financing to help accelerate Agendia’s commercial expansion in the US, Europe and Asia. Agendia operates a direct sales team in the US, the Netherlands, Italy, Germany, Switzerland and Austria, with a distributor network servicing the rest of the world. The company maintains a pipeline of genomic products and collaborates with pharmaceutical companies, leading cancer centres and academic groups on companion diagnostics and trials such as ISPY‑2 and MINDACT. Agendia develops and markets genomic-based diagnostic products to help support physicians with complex treatment decisions. Its breast cancer Symphony suite includes MammaPrint (an FDA-cleared IVDMIA breast cancer recurrence assay), BluePrint, TargetPrint and TheraPrint. The company recently launched the Symphony suite and plans to expand its commercialization. Agendia is also developing a personalized medicine pipeline and is preparing to launch ColoPrint, a recurrence test for stage II colon cancer prognosis and prediction. The company is led by CEO David Macdonald and is based in Boston, MA. It raised $65M in equity financing to support these commercialization and development efforts. Agendia develops molecular diagnostic tests for cancer, including MammaPrint, an in vitro diagnostic multivariate index assay (IVDMIA). The company plans to use the recent proceeds to accelerate commercialization of MammaPrint in the U.S. market. Agendia announced the closing of a $23m Series E financing to support that effort. The round included a lead investment from an undisclosed firm that provided approximately 50% of the funds, two independent entrepreneurs who invested $1m each, and additional capital from the company’s existing investor base. Dr. Bernhard Sixt, President and CEO, commented that the proceeds will be used to accelerate U.S. commercialization. The company is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

Total raised

$144M

Funding rounds

4

Latest round

Equity

Latest activity

Jul 2018